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DObjective: To compare the outcomes between minimally invasive coronary artery bypass (MINI-CAB) and
drug-eluting stent (DES) implantation for isolated left anterior descending artery disease.
Methods: Randomized and observational comparative publications were identified using MEDLINE and
Google Scholar databases (January 2003 to December 2013). Studies without outcomes data, without DES
use, or using conventional bypass surgery were excluded. The outcomes of interest were cardiac death, myocar-
dial infarction, target vessel revascularization, and periprocedural stroke. Data were compared using theMantel-
Haenszel methods and are presented as odds ratios (ORs), 95% confidence intervals (CIs), and number needed
to treat.
Results: From 230 publications, we identified 4 studies (2 randomized and 2 observational) with 941 patients
(478 had undergone MINI-CAB and 463 DES implantation). The incidence of target vessel revascularization at
maximum follow-up (range, 6-60 months) was significantly lower in the MINI-CAB group (OR, 0.16; 95% CI,
0.08-0.30; P< .0001; number needed to treat, 13). The incidence of cardiac mortality and MI was similar
between the MINI-CAB and DES groups during follow-up (OR, 1.05; 95% CI, 0.44-2.47; and OR, 0.83;
95% CI, 0.43-1.58, respectively). In addition, a similar incidence of periprocedural death (OR, 0.85; 95%
CI, 0.21-3.47; P ¼ .82), myocardial infarction (OR, 0.98; 95% CI, 0.38-2.58; P ¼ .97), and stroke
(OR, 1.36; 95% CI, 0.28-6.70; P ¼ .70) was observed between the 2 treatment modalities.
Conclusions: Given the available evidence, MINI-CAB will result in lower target vessel revascularization rates
but otherwise similar clinical outcomes compared with DESs in patients with left anterior descending artery
disease. (J Thorac Cardiovasc Surg 2014;148:1837-42)Patients who develop coronary artery disease in the left
anterior descending coronary artery (LAD) will have a large
amount of viable myocardium at risk and will be prone to
cardiovascular events, including myocardial infarction
(MI), ischemic cardiomyopathy, and sudden cardiac
death.1,2 Coronary revascularization has, therefore, been
recommended to improve the symptoms and clinical
outcomes of these patients. However, the optimal
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The Journal of Thoracic and CarCoronary artery bypass grafting (CABG) when performed
with the left internal mammary artery (LIMA) to LAD
graft can provide excellent long-term outcomes but at the
cost of an increased risk of complications compared with
less invasive percutaneous coronary intervention (PCI).
Randomized studies in the early era of PCI failed to match
the outcomes obtained with CABG, primarily because of a
greater need for repeat revascularization owing to resteno-
sis.6-8 However, with the introduction of drug-eluting stents
(DESs) a dramatic reduction in restenosis was seen
compared with bare metal stents or balloon angioplasty
alone. As such, much of the long-term advantages of
CABG were thought to have been eliminated.9,10 In those
settings in which the percutaneous treatment options will
be equally effective, most cardiologists, as well as
patients, have currently preferred PCI with DES
implantation instead of CABG, primarily owing to the
desire to avoid complications such as stroke and renal
failure and the longer period to full recovery.11,12
However, subsequent advances in CABG have led to
minimally invasive techniques that allow LIMA to LAD
grafting on the beating heart using smaller sternal-sparing
incisions.13-15 The major rationale for these techniquesdiovascular Surgery c Volume 148, Number 5 1837
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
DES ¼ drug-eluting stent
LAD ¼ left anterior descending artery
LIMA ¼ left internal mammary artery
MI ¼ myocardial infarction
MINI-CAB ¼ minimally invasive coronary artery
bypass
PCI ¼ percutaneous coronary intervention
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Dhas been to avoid stroke or systemic embolization by
avoiding crossclamping the aorta and avoiding the costs
and morbidity associated with the cardiopulmonary
bypass circuit.16 We performed a meta-analysis to compare
the outcomes from minimally invasive coronary artery
bypass (MINI-CAB) using LIMA to LAD grafting with
PCI using DESs for the management of LAD disease.METHODS
Inclusion Criteria
To be eligible for inclusion in our meta-analysis, the studies had to have
(1) compared MINI-CAB with DES for LAD revascularization and (2)
reported the outcomes for 1 clinical outcomes (ie, death, MI, stroke,
target vessel revascularization [TVR]) during the periprocedural period
and at 6 months of follow-up.
Search Strategy
A literature search was performed usingMEDLINE andGoogle Scholar
databases on all studies published of human subjects from January 1, 2003
to December 29, 2013. We used 2003 as the starting point, because DES
technology was not commercially available in most catheterization labora-
tories before 2003. We combined 3 searches that used the following search
headings: ‘‘percutaneous coronary intervention,’’ ‘‘PCI,’’ or ‘‘stent’’
(search 1); ‘‘minimally invasive direct,’’ ‘‘endoscopic atraumatic,’’ ‘‘totally
endoscopic,’’ ‘‘port-access,’’ or ‘‘coronary artery bypass’’ (search 2); and
‘‘left anterior descending,’’ ‘‘LAD’’, or ‘‘single vessel disease’’ (search
3). To broaden the search, we also used the ‘‘related articles’’ function.
All abstracts were reviewed, and no language restrictions were applied.
The search resulted in 230 studies (Figure 1). After a review of the titles
and abstracts, we found 20 studies that required a full text review. From
these studies, we excluded those reporting on outcomes of patients with
multivessel disease who had undergone multivessel revascularization
(n ¼ 1), same cohort studies with different follow-up periods (n ¼ 1),
studies using bare metal stents or balloon angioplasty (n¼ 12), and studies
using conventional CABGwith median sternotomy (n¼ 2). The remaining
studies were included in the present meta-analysis.
Statistical Analysis
Ourmeta-analysis was performed in linewith the recommendations from
the reporting of meta-analysis guidelines for observational studies.17 The
categorical outcomes data are reported as an odds ratio (OR) statistic, in
which an OR of<1 favored the surgical group. We used a random effects
model with theMantel-Haenszel method, in which it was assumed that vari-
ation existed among the studies owing to the varying risk profiles and selec-
tion criteria among the centers. The calculated OR, therefore, had a more
conservative value. Heterogeneity was assessed and reported using the
Cochran C statistic. Data inconsistency was reported using I2 tests, in which1838 The Journal of Thoracic and Cardiovascular Sura score of 25%, 50%, and 75% indicated a low, moderate, or high level of
data inconsistency, respectively. To translate ORs into benefits to clinical
outcome, we calculated the number needed to treat, which is the inverse
of the risk difference between the 2 treatment groups. For studies that con-
tained a 0 in the cell for the number of events of interest in either 1 of the
groups, we added the value of 0.5 in each cell of the 23 2 table for the study
in question. This correction was necessary, because cells with 0 events will
create problems with the computation of the ratio measures and standard er-
rors of treatment effects. Analyses were performed using Comprehensive
Meta-Analysis software, version 2 (Biostat, Englewood, NJ).RESULTS
Study Characteristics
A total of 4 studies published from 2005 to 2013 that
matched the inclusion criteria for comparing MINI-CAB
versus DES implantation for isolated LAD revasculariza-
tion.12,18-20 These studies had included 941 patients, of
whom 51% had undergone MINI-CAB and 49% DES im-
plantation. Both reviewers had 100% agreement on data
extraction. The study designs involved 2 randomized
controlled trials (n¼ 319) and 2 observational studies using
propensity score methods to adjust for confounding
(n ¼ 622). The maximum follow-up ranged from 6 to 60
months. The characteristics of these studies are listed in
Table 1.Patient and Procedural Characteristics
An overview of the patient and procedural characteristics
is listed in Table 2. The patients were, on average, in their
mid-60s (range, 61-66 years) and were predominantly
male (range, 64%-80%). The occurrence of diabetes ranged
from 21% to 60%, andmost patients had preserved left ven-
tricular ejection fraction without a history of MI. Coronary
angiography showed that the treated lesions were predomi-
nantly complex lesions, either type B2 or C. In the 2 obser-
vational studies, the total occluded LAD lesions were
numerically more common than in the MINI-CAB
group.18,19 Sirolimus-eluting stents were used exclusively
in 2 studies.12,18 Overall, sirolimus-eluting stents were
used in 70% of patients (n ¼ 324) and paclitaxel-eluting
stents in 30% of patients (n¼ 139). Surgical access was per-
formed using a left anterolateral thoracotomy (5-8 cm) be-
tween the fourth or fifth intercostal space. In 3 studies, the
ribs were retracted to allow LIMA harvesting and anasto-
mosis to the LAD under direct vision.12,18,20 In 1 study,
the LIMA was harvested using a thoracoscopic approach,
and the anastomosis was performed using endoscopic
stabilization devices without rib retraction.19 All procedures
were performed without the use of cardiopulmonary bypass.Postprocedural Outcomes
As shown in Figure 2, the postprocedural outcomes for
death, MI, stroke, and TVR were infrequent and also not
significantly different statistically between MINI-CAB and
DES implantation. Two studies reported the postproceduralgery c November 2014
FIGURE 1. Consort diagram. LAD, Left anterior descending artery.
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Dhospital days, and both showed a longer length of stay after
MINI-CAB than after DES implantation (mean, 4.4  2.0
days vs 3.6 1.5 days; P¼ .017; andmedian, 8 days; range,
7-9; vs median, 1; range, 1-1; P<.0001).12,20
Cardiac Death at Maximum Follow-up
All 4 studies reported on cardiac mortality at the
maximum follow-up point. A meta-analysis of the studies
did not show any significant differences in cardiac deathTABLE 1. Characteristics of studies included in the meta-analysis
Characteristic Hong and colleagues20 Ben-Gal and c
Study design RCT Coho
Year published 2005 2006
Enrollment period 2003 2002-2
Country South Korea Israe
Patients (n) 189 166
MINI-CAB Direct vision Direct v
Stent type PES/SES SES
Follow-up (mo) 6 23
Contact Office visit Telephone,
Catheterization at follow-up No No
Definition proc MI Q-wave, CK-MB —
RCT, Randomized clinical trial;MINI-CAB, minimally invasive coronary artery bypass; PE
dial infarction; CK-MB, creatine kinase MB-fraction. *Enrollment varied between the 2 gr
matched coronary stent group, from 2002 to 2005.
The Journal of Thoracic and Carat the maximum follow-up point between the 2 groups
(OR, 1.05; 95% confidence interval [CI], 0.44-2.47;
Figure 3). Information on all-cause mortality was also avail-
able in all studies and rendered similar results (OR, 1.16;
95% CI, 0.69-1.95; P ¼ .58).
MI at Maximum Follow-up
Similar to cardiac death, a meta-analysis of the 4 studies
did not show any significant difference in the incidence ofolleagues18 Thiele and colleagues12 Etienne and colleagues19
rt RCT Cohort
2009 2013
003 2003-2007 1997-2011*
l Germany Belgium
130 456
ision Direct vision Thoracoscopic
SES PES/SES
12 60
records Office visit Office, records
Yes No
Q-wave, CK-MB Q-wave, troponin
S, paclitaxel-eluting stent; SES, sirolimus-eluting stent; proc MI, procedural myocar-
oups: in the surgical group, the patients were included from 1997 to 2011 and, in the
diovascular Surgery c Volume 148, Number 5 1839
TABLE 2. Patient and procedural characteristics
Variable
Hong and colleagues20 Ben-Gal and colleagues*,18 Thiele and colleagues12 Etienne and colleagues19
MINI-CAB DES MINI-CAB DES MINI-CAB DES MINI-CAB DES
Patient characteristics
Patients (n) 70 119 83 83 65 65 260 196
Age (y) 61  10 61  10 >70 (39) >70 (39) 66 (59-71) 66 (59-72) 63  12 62  12
Male gender (%) 64 64 80 80 71 69 75 74
Diabetes (%) 49 37 29 30 25 28 21 60
Previous MI (%) 23 22 34 29 23 23 12 21
CVD (%) 3 3 — — 9 3 — —
UA (%) 43 50 — — — — 41 40
LVEF (%) 52  9 53  9 <30 (7) <30 (1) 65 (60-70) 65 (60-66) <30 (8) <30 (1)
Procedural characteristics
Total occlusion (%) 0 0 24 2 0 0 13 3
Bifurcation lesion (%) — — 10 10 0 0 — —
B2/C lesion (%) 76 76 — — 54 62 — —
Lesion length (mm) 19  4 20  5 — — 12 (10-18) 12 (10-17) — —
Stent length (mm) 23  5 — 13 (13-18) —
Stent diameter (mm) 2.9  0.3 — 3 (3-3.5) —
Data presented as mean standard deviation or median (range), except as noted.MINI-CAB, Minimally invasive coronary artery bypass;DES, drug-eluting stent;MI, myocardial
infarction; CVD, cerebrovascular disease; UA, unstable angina; LVEF, left ventricular ejection fraction. *Data in parentheses are number of patients.
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(OR, 0.83; 95% CI, 0.43-1.58; Figure 3).
TVR at Maximum Follow-up
A meta-analysis of the included studies showed a signif-
icantly lower incidence of TVR after MINI-CAB (2.5%)
than after DES implantation (12.3%) at the maximum
follow-up point, with an OR of 0.16 (95% CI, 0.08-0.30;
P< .0001). The risk difference between MINI-CAB and
DES was 7.7% (range, 1%-14%; number needed to treat,
13; Figure 3).
DISCUSSION
Revascularization of patients with isolated LAD disease
has evolved significantly by advances in interventional
and surgical techniques. The current guidelines support
the use of a revascularization strategy in patients with sig-
nificant proximal LAD disease (using angiographic and
fractional flow reserve criteria) to alleviate symptoms andFIGURE 2. Summary of average differences in periprocedural outcomes.MINI
OR, odds ratio; CI, confidence interval.
1840 The Journal of Thoracic and Cardiovascular Surimprove the prognosis.5 PCI with DESs has become the
first-line intervention for most patients with isolated prox-
imal LAD lesions. However, the findings from our meta-
analysis suggest that for isolated LAD revascularization,
the use of MINI-CAB will result in more definitive revascu-
larization comparedwith DESs, although at the expense of a
longer initial postprocedural recovery. A number of reasons
could explain the difference in outcomes between MINI-
CAB and PCI. First, a significant proportion of the treated
LAD lesions in our meta-analysis were lesions with high
complexity. Previous studies have shown that lesion
complexity is an important predictor for procedural success
and repeat revascularization procedures after DES implana-
tion.21 Surgical techniques will be much less affected by
lesion complexity and as such will have lower TVR rates.
Second, unlike the LIMA graft, coronary stents that include
DESs only treat the affected segment but will not be effec-
tive in providing revascularization in progressive coronary
artery disease in the LAD.-CAB, Minimally invasive coronary artery bypass;DES, drug-eluting stent;
gery c November 2014
FIGURE 3. Forest plot showing results from meta-analysis of studies reporting cardiac death, myocardial infarction, and repeat revascularization after
minimally invasive coronary artery bypass compared with drug-eluting stents. MINI-CAB, Minimally invasive coronary artery bypass; DES, drug-
eluting stent; OR, odds ratio; CI, confidence interval; MI, myocardial infarction; TVR, target vessel revascularization.
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DMINI-CAB and Newer Generation DESs
Recent studies have shown that newer generation DESs,
such as the everolimus-eluting and zotarolimus-eluting
stents, will further reduce the risk of MI, reintervention,
and stent thrombosis compared with sirolimus-eluting
and paclitaxel-eluting stents.22,23 Currently, a number of
randomized studies are ongoing to assess the comparative
effectiveness of these newest generation DESs against
conventional CABG in patients with multivessel disease
and/or unprotected left main disease (ClinicalTrials.gov
Identifiers, NCT01205776 and NCT01311323). Given the
rapid advances in surgical techniques to further reduce
postprocedural morbidity, future studies are also needed
to assess the efficacy and safety of these techniques in the
setting of proximal LAD disease compared with
conventional stenting.Adoption of MINI-CAB in Current Clinical Practice
and Future Prospects
MINI-CAB could present an attractive alternative to con-
ventional CABG, because it omits the risks of deep sternal
wound infections and the problems with sternal healing and
results in a shorter length of hospital stay and interval to full
recovery, with equal safety and efficacy in experienced sur-
gical centers.24-27 Despite these advantages, the adoption of
MINI-CAB has been slow, and the use of coronary stents for
isolated LAD disease has been the default revascularizationThe Journal of Thoracic and Carstrategy. The low use of MINI-CAB can, in part, be ex-
plained by the greater technical demands of this procedure
compared with conventional CABG, its restriction to revas-
cularization of isolated LAD and diagonal disease, and
finally, its invasiveness compared with DES. However, the
use of MINI-CAB could regain popularity, because recent
studies of ‘‘hybrid coronary revascularization’’ (in which
MINI-CAB is combined with DESs for non-LAD lesions)
have shown promising results compared with conventional
surgery.28
The findings of our meta-analysis have reinforced the
need for a multidisciplinary heart team approach to discuss
all treatment options for patients with isolated LAD disease,
including the role of MINI-CAB, and to select the most
appropriate treatment strategy for individual patients.
Although the current guidelines have provided recommen-
dations for the use of MINI-CAB, a recently published
statement document on optimizing outcomes and the future
prospects of CABG proposed including MINI-CAB in the
decision tree for revascularization in patients with isolated
LAD disease.29Study Limitations
Our study had several limitations. First, the inclusion
criteria, study design, treatment protocols, and outcome
assessment varied across the studies. Second, our study
included observational data, which is prone to selectiondiovascular Surgery c Volume 148, Number 5 1841
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Dbias and confounding, despite applying proper adjustment
methods. Third, among the randomized studies, both the
treatment allocation and the assessment of clinical out-
comes were unblinded. Fourth, owing to the variation in
definitions of events and data collection and the use of
scheduled angiographic follow-up, we noted increased het-
erogeneity among some of the outcomes among the
included studies. Finally, a publication bias could not be
ruled out, because meta-analyses can only report on the out-
comes of published studies.
CONCLUSIONS
In patients who underwent isolated LAD revasculariza-
tion, the use of MINI-CAB resulted in lower TVR rates
and similar rates of cardiac death and MI at midterm
follow-up compared with PCI with DESs.
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